Presenter's Information

Gregg W. Stone, MD

Country USA
Specialty Interventional Cardiologist
  1. A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients with HFrEF and HFpEF: Principal Results from the RELIEVE-HF Trial
  2. MitraClip Treatment of Secondary MR in Heart Failure: Final 5-Year Results from COAPT
  3. BRIGHT-4 Trial; Bivalirudin with a Post-PCI High-Dose Infusion vs. Heparin Monotherapy During Primary PCI in STEMI
  4. How to Treat: Left Main & 3 Vessel Disease
  5. Left Main Revascularization: Data Supports PCI in Most Cases
  6. Which Patients with Stable CAD Benefit from PCI in the Post-ISCHEMIA Era?
  7. Left Main PCI vs. CABG: Form the Final EXCEL Outcomes to Patient Recommendations
  8. Transcatheter Mitral Valve Repair: Guideline Changes, Evidence Gaps and Future Directions
  9. New Insights from the COAPT: Patient Eligibility and Timing
  10. EXCEL Trial: Extended Long-term and Key Clinical Substudies
  11. Mitral Valve: Future Perspectives
  12. Long-term and Updated Data from EXCEL and NOBLE
  13. ONYX One and ONYX One CLEAR Trials of 1-month DAPT After Onyx
  14. The COAPT Trial: How the Trial Succeed?
  15. Deep Dive into Mitraclip Trials for Functional MR
  16. Long-term Outcomes and More Data from ABSORB Trials
  17. FFRCT to Guide Revascularization Decisions: The DECISION Trial
  18. COAPT
  19. Inter-Atrial Shunts in HF: Devices, Indication, and Outcomes
  20. Future Perspectives of BRS, Will It Go Forward or Not?
  21. XIENCE Safety ; Review of XIENCE DAPT Clinical Evidence and Clinical Program
  22. ABSORB IV: 30-day Outcomes from a Randomized Trial of a Bioresorbable Scaffold Versus a Metallic DES in Patients with Coronary Artery Disease
  23. ABSORB III, IV, Updated Meta, and More - Expert Future Expectation on Bioabsorbable Scaffolds
  24. Clinical Trials in Functional Mitral Regurgitation
  25. [Satellite Lecture] PCI Outcomes with Bioresorbable Scaffolds: Role of Technique and DAPT
  26. [Satellite Lecture]Congratulatory Remark & Keynote Lecture: “Left Main Intervention Comes of Age: A 40-Year Odyssey from Balloon Angioplasty to Drug-Eluting Stents”
  27. The Future PROSPECT for the Role of Antiplatelet Therapy
  28. Why Do We Need a Fully Bioresorbable Vascular Scaffold; From Absorb III and ABSORB Meta-Analysis to the Future
  29. ABSORB III - Current and Future Use of Bioresorbable Scaffolds
  30. Drug-Eluting Stents vs. Bioresorbable Vascular Scaffolds: Is Newer Better?  
  31. Management of Stable Coronary Heart Disease with Objective Ischemia: COURAGE, FAME2 and Recent Meta-Analysis
  32. BRS: From ABSORB III to the Future
  33. Left Main PCI: Anticipating EXCEL
  34. PLATO: Impact on the Management of ACS and Personalizing Treatment with Ticagrelor
  35. Evolution, BVS Unique Benefits, Clinical Perspectives on Angina
  36. UFH Versus Bivalirudin: Which One Should I Use?
  37. Focal Treatment of Vulnerable Plaque: Stents, Scaffolds and Prospect II
  38. Future Roadmap of the Mitral Valve Therapies
  39. Vulnerable Plaque Detection and Treatment: PROSPECT II and PROSPECT ABSORB
  40. Bioresorbable Scaffolds in a "Nutshell": Updates and Expectations
  41. Lessons from the Pooled Data using Xience Everolimus-eluting Stent
  42. Evidence-based Pharmacotherapy for ACS Patients: The Forest and the Trees
  43. Reduction of Thrombus: Routine vs. Selective Aspiration
  44. Current Status of EXCEL Study
  45. New Insights Regarding the Safety and Efficacy of DAPT After Stenting
  46. Latest Update of PLATINUM Trial: Promus Element Workhorse Two Year Follow-up
  47. PCI Today: Best Practices, Optimal Outcomes, and Limitations: When Do I Prefer CABG for MVD?
  48. What’s Known and Unknown about LM PCI: Transitioning from SYNTAX to EXCEL
  49. PLATINUM Workhorse Data from ACC
  50. Xience Platform Safey Update
  51. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease (SPIRIT IV)
  52. The EXCEL Trial
  53. DES in Left Main Disease: New Guidelines and Updates from EXCEL
  54. Motivation, Objective and Implication of EXCEL Study
  55. Bioabsorble or Free-Polymer DES: Current and New Technologies
  56. Milestone for Left Main PCI: Upcoming Excel LM Trial
  57. Does PROSPECT Support the Use of Invasive Imaging to Diagnose and Treat Vulnerable Plaque with DES?
  58. Introducing EXCEL: The \"Definitive\" Unprotected Left Main Randomized Trial!
  59. The Latest Updates in DES Clinical Data
  60. STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Weight Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel, and Prasugrel)
  61. Linkage of Current Plaque Vulnerability to Future Events: Evidence from PROSPECT Study
  62. HORIZONS AMI: A Large Prospective Randomized Trial of PES vs. BMS in Patients with STEMI
  63. Comparison of DES versus BMS in Real World Registries
  64. New Paradigms of Care for ST-Elevation Myocardial Infarction (STEMI): Focusing on Mortality and Attributable Death Analysis in Cath-Based Care: What Do Device and Drug Trials Teach Us?
  65. Revived Indications for Thrombus Aspiration During Primary PCI: Unanswered Questions after TAPAS
  66. HORIZONS AMI: Implications for Pharmaco-Adjunctive Therapy and DES Use
  67. HORIZONS AMI AMI: Prospective Randomized Trials of Paclitaxel-Eluting Stents vs. BMS in Patients with STEMI
  68. COOL RCN : Randomized Trail of Systemic Hypothermia for Prevention of Radiocontrast Nephropathy
  69. Bivalirudin for the Best Overall Outcomes and Most Cath Lab Compatible
  70. SPIRIT III (US Pivotal Study Results for Xience V Everolimus Eluting Coronary Stent)
  71. Taking the Evidence-Based Approach to ACS: Examination of New Antithrombin Trial Data
  72. SPIRIT-III: Clinical, Angiographic and IVUS Results from the Pivotal United States Randomized SPIRIT-III Trial of the Xience V Everolimus Eluting Coronary Stent System in Patients With Coronary Artery Disease
  73. ACUITY PCI: A Prospective Trial of Patients With Acute Coronary Syndromes Undergoing PCI After Randomization to Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibitors: 30-Day Clinical and Angiographic Core Laboratory Results
  74. The Baseline Clinical Features and Plaque Characteristics from the PROSPECT Trial
  75. Should DES Use be Reduced Due to Safety Concerns? Important Messages from the Randomized DES Trials
  76. 2007 Guidelines Update for DES: An Evidence-Based Medicine Critical Analysis
  77. Evidence-Based Medicine Analysis of Current DES Clinical Use Guidelines: A Roadmap for Clinicians
  78. Taxus V Clinical Update
  79. Optimizing Outcomes of Primary PCI: From CADILLAC to HORIZONS
  80. EMERALD Trial: Lessons Learned
  81. Zen Philosophy - The KEY to CTO Success
  82. Evidence-Based Medicine Analysis of Current DES Clinical
  83. Recent Updates from the Taxus Trials (Taxus 2 and 4 Late FU, Taxus Meta-Analysis, and Taxus 5)
  84. Paclitaxel-Eluting TAXUS Stents Strengths and Weaknesses
Conference Slides
Category